An evaluation of human recombinant α interferon in patients with metastatic gastrinoma

摘要: Abstract Background: Metastatic gastrinoma is becoming increasingly recognized in patients with Zollinger-Ellison Syndrome. The mean 5-year survival of these Methods: efficacy and toxicity interferon was assessed 13 consecutive syndrome liver metastases. Patients were treated human recombinant α (5 million IU, subcutaneously [SC]) daily followed up at 3-month intervals multiple imaging studies. At each follow-up, therapy fasting serum gastrin concentrations obtained. Results: No patient showed a reduction tumor size any follow-up. One died after 2 months. 6 months, six (46%) had stable the liver, although new bone metastases developed one patient. Three disease for to 21 Changes correlated response All some side effects therapy. Thirty-one percent required dose reduction, (8%) have interrupted briefly. Conclusions: These results fail define therapeutic role treatment metastatic gastrinoma.